# A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer

> **NCT01152437** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 94 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** BIBW 2992
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT01152437
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2012-03
- **Final completion:** —
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2014-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01152437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01152437, "A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01152437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*